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Background: To investigate the incidence and risk of severe late toxicity with concurrent chemoradiotherapy
(CCRT) in nasopharyngeal carcinoma patients.
Methods: Eligible studies included prospective randomized controlled trials (RCTs) evaluating CCRT versus
radiotherapy alone in patients with nasopharyngeal carcinoma and in which data on severe late toxicities were
available. Random effects or fixed effect models were applied to obtain the summary incidence, relative risks (RRs)
and 95% confidence intervals (CIs).
Results: Five RCTs with 1102 patients with NPC were included in this analysis. The summary incidence of overall
severe late toxicities in patients receiving CCRT was 30.7% (95% CI, 18–47.2%) and the incidence of radiotherapy alone
group was 21.7% (95% CI, 13.3–33.4%). The use of concurrent chemotherapy was associated with an increased risk of
severe late toxicities, with a RR of 1.349 (95% CI, 1.108–1.643; P = 0.005). As for specific late toxicity, CCRT significantly
increased the risk of ear deafness/otitis (RR = 1.567; 95% CI, 1.192–2.052), but other late toxicities were not significantly
different. Patients receiving concurrent chemotherapy regimens with 3-week high-dose cisplatin (HC) have a higher risk
of ear deafness/otitis (RR = 1.672; 95% CI, 1.174–2.382; P = 0.026). However, there was no significant increase in the RR
of severe ear complication with the addition of non-3-week high-dose cisplatin (nonHC) regimens (RR = 1.433; 95% CI,
0.946–2.171; P = 0.095).
Conclusion: With the present evidence, the addition of concurrent chemotherapy seems to increase the risk of severe
late toxicities in patients with NPC, especially when using HC regimen for the occurrence of severe ototoxicity.
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Nasopharyngeal carcinoma (NPC) is sensitive to radi-
ation, but the outcomes of patients with advanced-stage
NPC were unsatisfactory [1,2]. Given the chemosensitive
nature of NPC, the combination of chemotherapy and
radiation has been investigated for advanced NPC. No
consensus on the optimal protocol had been reached
until the Intergroup 0099 study [3], which demonstrated* Correspondence: yinghongmei2011@sina.com
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vant chemotherapy using cisplatin-based chemotherapy
was superior to radiation therapy alone. Subsequently,
evidence increasingly mounted from randomized trials
[4-8] and meta-analyses [9] confirming the advantage of
CCRT.
Although the superiority of CCRT for NPC has been
indisputable, there are concerns about the side effects
caused by the combination of concurrent chemotherapy
and radiotherapy. Severe acute toxicities could impair
the compliance of treatment. Severe late toxicities (grades is an Open Access article distributed under the terms of the Creative Commons
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patient’s quality of life (QoL) and functional status [10].
As the overall survival for NPC patients improves, late
toxicities may become more frequent. Concurrent chemo-
therapy was found to increase the acute toxicities during
radiotherapy [6-8]. However, the overall incidence and risk
of severe late toxicities with additional concurrent chemo-
therapy in NPC remain unknown because many of the
published data were based on studies that were either
retrospective, or with inadequate duration of observation
for full assessment of long-term toxicity, or were obscured
by treatment heterogeneity [11-13].
We conducted this meta-analysis of prospective ran-
domized controlled trials (RCTs) reporting severe late
toxicities to investigate the overall incidence and risk of
severe late toxicities with CCRT in NPC to help clini-
cians target possible severe late effects that need special
attention during patient follow-up.
Methods
We identified and selected relevant studies by searching
the databases: Web of knowledge, Embase, Cochrane li-
brary databases and Pubmed updated to August 2014.
The search was conducted by using the keywords “naso-
pharyngeal carcinoma”, “radiotherapy”, “chemotherapy”,
and “chemoradiotherapy” and was limited to human stud-
ies and clinical trials published in English. The reference
list of each article obtained was checked for further poten-
tial studies. Only RCTs in which CCRT was compared
with radiotherapy alone in NPC patients and the detailed
data on severe late toxicities were reported, were eligible
for inclusion in the meta-analysis. The report quality of
the clinical trials was assessed and calculated using Jadad
scale including randomization, double-blinding, and with-
drawals as previously described [14].
Data from the studies were extracted independently by
two investigators (CD and FK) using standardized data
forms and disagreement was resolved by consensus. The
following information was extracted: author’s name,
publication year, number of enrolled subjects, treatment
arms, number of patients in each group, the duration of
follow-up and events of severe late toxicities. This study
was performed with the approval of Institutional Review
Boards of Fudan University Shanghai Cancer Center.
Statistical analysis
The pooled analysis of incidence and RR were performed
with Open Meta-Analyst software version 3.13. The
publication bias was tested with Stata/SE 12.0. A classic
half-integer continuity correction was applied to obtain
the relative risk (RR) and variance for studies reporting
zero events in a treatment or control arm. Between-
study heterogeneity was estimated using chi-squared and
I2 tests. Heterogeneity was considered statisticallysignificant when P < 0.05 or I2 > 50%. If heterogeneity
existed, data was analyzed using a random effects model.
In the absence of heterogeneity, a fixed effects model was
used. The RR was considered significant when P value
was less than 0.05 (2-tailed), with values of <1 favoring
concurrent chemoradiotherapy. The presence of publica-
tion bias was assessed with the Begg’s [15] and Egger’s
tests [16].
Results
Patients characteristics and quality assessment
Through the electronic databases, a total of 1968 citations
were searched. Initially, 932 studies were excluded for du-
plicate. After screening through titles and abstracts, a total
of fifty-two randomized controlled trials (RCTs) investi-
gating CCRT versus radiotherapy in patients with NPC
were identified. The data on the severe late toxicity were
reported in 5 studies [17-21], which were further included
in the meta-analysis. Figure 1 shows the selection process
in detail.
The main characteristics of the included studies are pre-
sented in Table 1. Patients in Lee’s trial [18] were ran-
domized to receive conventional-fractionation RT
alone (CF group), accelerated-fractionation RT alone (AF
group), conventional-fractionation RT plus concurrent-
adjuvant chemotherapy (CF + C group), or accelerated-
fractionation RT plus concurrent-adjuvant chemotherapy
(AF + C group). Only the patients in CF group and CF + C
group were included in our analysis. The included RCTs
had a median follow-up of at least 5 years. A total of 1102
patients with histologically proven NPC were available for
the meta-analysis. There were 547 patients in CCRT group
and 555 in RT group. Late toxicity in all the included trials
was graded according to Late Radiation Morbidity Scoring
Criteria of the Radiation Therapy Oncology Group [22].
Severe late toxicity was defined as grade 3, 4 and 5 taken
together.
All the included trials reported withdrawals and drop-
outs. Four trials had mentioned the concealment of allo-
cation clearly in the randomization process and had
Jadad scores of 3. One trial did not mention the method
of generating sequence of randomization and had Jadad
scores of 2.
Incidence and RR of overall severe late toxicities
For total types of severe late toxicities, there were 150
events among 547 NPC patients that received CCRT,
conferring a summary incidence of 30.7% (95% CI, 18–
47.2%; heterogeneity test: P < 0.001; I2 = 47.7%). There
were 118 events among 555 patients receiving RT alone,
with an incidence of 21.7% (95%CI, 13.3–33.4%; hetero-
geneity test: P < 0.001; I2 = 46.3%). The summary RR of
overall severe late toxicities for CCRT versus RT was
1.349 (95% CI, 1.108–1.643; P = 0.005) (Figure 2),
Figure 1 CONSORT diagram: flow chart of trail selection process for the meta-analysis.
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NPC patients receiving CCRT. No significant heterogen-
eity was observed (Q = 1.592; P = 0.81; I2 = 0.0%).
Incidence and RR of specific late toxicity
The pooled analysis of the incidence and RR of specific
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Figure 2 Relative risk of severe late toxicities with the addition of concurrent chemotherapy.
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ing concurrent chemotherapy regimens with 3-week
high-dose cisplatin (HC) have a higher risk of ear deaf-
ness (RR = 1.672; 95% CI, 1.174–2.382; P = 0.026). How-
ever, there was no significant increase in the RR of
severe ototoxicity with the addition of non-3-week
high-dose cisplatin (nonHC) regimens (RR = 1.433; 95%
CI, 0.946–2.171; P = 0.095) (Table 3).
Publication bias
There was no evidence of publication bias for RR of
overall severe late toxicities by either the Begg’s or theTable 2 Incidence and relative risk (RR) of specific late toxicit
Late toxicities No. of studies No. of severe late toxicity
no. of patients
Chemoradiotherapy Ra
Overall late toxicities 5 150/547 118
Ear (deafness/otitis) 5 107/547 72/
Cranial neuropathy 4 19/431 21/
Soft tissue damage at neck 4 17/431 17/
Peripheral neuropathy 3 6/372 2/3
Temporal lobe necrosis 2 5/200 11/
Brachial plexopathy 2 0/214 1/2
Endocrine dysfunction 2 15/214 12/
Visual toxicity 2 3/200 3/2
Dysphagia 2 2/214 0/2
Bone necrosis 2 2/330 1/3
Mucosal damage 2 4/231 1/2
Radiation-induced malignancy 2 0/330 1/3Egger’s test (Begg’s P = 0.806 and Egger’s P = 0.687). No
publication bias for RR of severe deafness/otitis was
observed (Begg’s P = 0.806 and Egger’s P = 0.696).
Discussion
As far as we know, this is the first meta-analysis evaluat-
ing the incidence and risk of severe late toxicities associ-
ated with CCRT. In current study, we reviewed the
existing data on the severe late toxicities from RCTs in
NPC patients by a meta-analytical method. In this ana-
lysis, all the included RCTs have a median follow-up of
at least 5 years, which was considered to be a usefuly
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441 5.5(3.6-8.5) 5.2(3.4-7.9) 0.923(0.351-2.427)
441 4.6(2.9-7.2) 4.2(2.6-6.6) 1.007(0.522-1.94)
85 1.8(0.9-3.9) 1.6(0.5-5) 2.295(0.41-12.845)
209 2.9(1.3-6.5) 5.8(3.2-10.2) 0.47(0.079-2.809)
27 0.6(0.1-4.1) 0.7(0.1-3.3) 0.567(0.048-6.707)
227 7.1(4.3-11.4) 5.3(3.1-9.2) 1.312(0.629-2.74)
09 2.4(0.8-7.2) 2.1(0.7-6.4) 1.14(0.236-5.507)
27 1.2(0.3-3.9) 0.5(0.1-3.6) 2.973(0.272-32.51)
34 0.6(0.2-2.4) 0.5(0.1-2.3) 1.622(0.201-13.111)
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33 0.3(0-2.1) 0.5(0.1-2.3) 0.524(0.044-6.226)
Table 3 Relative risk of severe ototoxicity by concurrent chemotherapy regimen
Study No. of events/patient size Relative risk 95% CI P value
CCRT RT
HC
Lee et al. (2011) [19] 22/42 12/51 2.226 1.256 to 3.947
Lee et al. (2010) [21] 37/172 27/176 1.402 0.895 to 2.198
Overall 1.672 1.174 to 2.382 0.026
Non-HC
Chen et al. (2013) [18] 28/158 18/158 1.556 0.898 to 2.695
Chen et al. (2011) [20] 12/116 8/114 1.474 0.626 to 3.471
Wu et al. (2013) [17] 8/59 11/56 1.085 0.421 to 2.794
Ovarall 1.433 0.946 to 2.171 0.095
CCRT: concurrent chemoradiotherapy; RT: radiotherapy; HC: 3-week high-dose cisplatin; non-HC: non-3-week high-dose cisplatin.
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our analysis that NPC patients treated with CCRT had a
significantly increased risk of severe late toxicities com-
pared with those given with RT alone. The incidence of
severe late toxicities for patients receiving CCRT was
30.7% compared with 21.7% for those treated with RT.
Whether the addition of concurrent chemotherapy in-
creases the incidence and severity of late toxicities in
NPC patients was controversial in the literature. These
findings could be explained by that the published data
on late toxicities induced by CCRT were usually from
studies that are small sample sizes, retrospective, in-
volved treatment heterogeneity, or with inadequate
follow-up [10-12].
Ototoxicity is the most common severe late toxicity,
accounting for almost two thirds of total severe late toxic-
ities in this analysis. CCRT incurred a significant 1.567-
fold increase in the risk of severe ototoxicity, which is not
surprising because both cisplatin and RT are known to
cause hearing loss. However, with weekly intermediate
dose of cisplatin or oxaliplatin (nonHC), the patients
didn’t experience a statistically significant increased risk.
No additive effect for weekly intermediate dose of cisplatin
on ototoxicity may be explained by that the dose level of
cisplatin given per infusion was too low to induce ototox-
icity by itself [23]. Although HC regimens had resulted in
favorable outcome for locally advanced NPC, it was as-
sociated with increased acute and poor compliance. In
the Intergroup 0099 study, only 63% of patients who
were scheduled to receive three courses of concurrent
100 mg/m2 cisplatin actually did so. This issue may be
overcome by the change of combination schedule of
cisplatin or the use of other anticancer agents. It’s re-
ported [24] that a weekly intermediate dose of cisplatin
could decrease interruptions in radiation treatment
and reduce acute toxic effects without compromising
local control. Weekly oxaliplatin combined concomi-
tantly with RT was also found to achieve a significantimprovement in therapeutic outcome with minimal
and acceptable additional toxic effects [14]. Thus, nonHC
regimens may be an alternative of treatment for NPC in
order to reduce the rate of ototoxicity.
Except for ototoxicity, the risk of other severe late tox-
icities didn’t increase with the addition of concurrent
chemotherapy in this analysis, for which we suggest sev-
eral possible explanations: the small number of events
recorded; underreporting of rare adverse events; the fact
that clinical trials are usually not designed specifically to
address toxic events; and the small number of random-
ized controlled trials included.
There are some limitations in this meta-analysis. First,
the follow-up duration of the included trials was inad-
equate for assessing all types of late toxicities. Five year
follow-up is long enough to assess the development of
ototoxicity but may be inadequate for neurological com-
plications, the median latency of which exceeds 5 years.
Kong et al. [25] reported that the occurrence of cranial
neurophathy increased with prolonged follow-up, reaching
44.5% at 20 years. But the included data in this analysis is
the most updated data we can get from RCTs. This limita-
tion can only be overcome by the further update of the
RCTs. Second, the number RTCs included in this analysis
is small. We have searched the Web of knowledge,
Embase, Cochrane controlled trials register and Pubmed
updated to August 2014, but only five RCTs fulfilled the
inclusion criteria. The data on severe late toxicities are un-
available in most of RCTs. Thus the updates of long term
results from RCTs are encouraged to provide a better
understanding of the potential adverse impacts of CCRT
on NPC patients. Third, this meta-analysis is based on
published data and tends to overestimate treatment effects
compared with individual patient data analyses.
Conclusion
This study demonstrates that the use of CCRT seems to
increase the risk of severe late toxicities in patients with
Du et al. Radiation Oncology  (2015) 10:70 Page 6 of 6NPC, especially when using HC regimen for the occur-
rence of severe ototoxicity. But one should be cautious
when interpreting these results due to the limitations of
our study. Additionally, as concurrent chemotherapy with
cisplatin gains greater clinical use, clinicians should be
aware of the risks of severe late toxicities with the addition
of high dose cisplatin and adequately explain these risks
to gain truly informed consent of our patients.
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